menu
    • menu
    [{"orgOrder":0,"company":"Cebina","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"H1 receptor","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Cebina","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Cebina \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Cebina \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"INDIA","productType":"Steroid","year":"2020","type":"Divestment","leadProduct":"Mometasone Furoate","moa":"||Glucocorticoid receptor","graph1":"Immunology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Glenmark Pharmaceuticals \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Dr. Reddy's Laboratories"}]

    Find Clinical Drug Pipeline Developments & Deals for Azelastine HCl

    Menu

    Azelastine HCl

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glenmark Pharmaceuticals

                            India arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Dr. Reddy's Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Glenmark to Sell Select Anti-Allergy Brands to Dr Reddy’s in Russia, Ukraine, Kazakhstan and Uzbekistan for ...

                            Details : The divested brand and its extensions represent two types of products, (a) Mometasone mono product and (b) combination of Mometasone with Azelastine, and are indicated for the treatment of Seasonal and Perennial Allergic Rhinitis.

                            Product Name : Momat Rino Advance

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            November 28, 2020

                            Lead Product(s) : Mometasone Furoate,Azelastine Hydrochloride

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Dr. Reddy's Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cebina

                            Austria arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Cebina

                            Austria arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azelastine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            CEBINA Reports Positive Findings on the Potency of Azelastine, a Widely Used Anti-Histamine, as Anti-Covid-19 ...

                            Details :

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 17, 2020

                            Lead Product(s) : Azelastine Hydrochloride

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth